Citius Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2013	2012
Net Income	-33.69	-33.64	-24.51	-17.55	-15.56	-12.54	-10.38	-8.3	-2.9	-1.29	Upgrade
Depreciation & Amortization	0.19	0.18	0.16	0.15	0	0	0	0	0	0	Upgrade
Share-Based Compensation	6.72	4.28	1.52	1.33	0.93	0.78	0.99	0.73	0.49	0	Upgrade
Other Operating Activities	-3.43	0.82	-2.88	-0.87	2.2	0.44	1.42	1.66	0.03	0.19	Upgrade
Operating Cash Flow	-29.06	-28.36	-24.25	-16.93	-12.44	-11.32	-7.97	-5.9	-2.39	-1.1	Upgrade
Capital Expenditures	0	0	-0.01	-0	0	0	-0	0	0	0	Upgrade
Acquisitions	0	0	0	0	0	0	0	0.26	0	0	Upgrade
Other Investing Activities	-	-	-40	-	-	-	-	-	-	-	Upgrade
Investing Cash Flow	0	0	-40.01	-0	0	0	-0	0.26	0	0	Upgrade
Share Issuance / Repurchase	13.83	0	120.64	22.73	11.15	17.3	6.67	5.43	1.51	0	Upgrade
Debt Issued / Paid	0	0	-0.17	0.16	0	0	4.21	-0.1	0	1.13	Upgrade
Other Financing Activities	-	-	0	-	-	-	-	-0.06	-	-0.03	Upgrade
Financing Cash Flow	13.83	0	120.47	22.9	11.15	17.3	10.88	5.26	1.51	1.11	Upgrade
Net Cash Flow	-15.23	-28.36	56.21	5.97	-1.29	5.98	2.91	-0.38	-0.88	0.01	Upgrade
Free Cash Flow	-29.06	-28.36	-24.26	-16.93	-12.44	-11.32	-7.97	-5.9	-2.39	-1.1	Upgrade
Free Cash Flow Per Share	-0.19	-0.19	-0.22	-0.43	-0.62	-1.05	-1.45	-1.63	-1.12	-0.93	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).